Lantern Pharma warns resources won't cover 12 months
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Lantern Pharma Inc. reported a $9.7 million net loss for the nine months ended September 30, 2026, versus $13.0 million a year earlier, and used $10.1 million in operating cash. Third-quarter net income was $696,615, including a $6.0 million warrant-liability fair-value gain; diluted loss per share was $0.37.
At September 30, cash and cash equivalents were $7.6 million, marketable securities were $10,882, and working capital was approximately $2.759 million. Lantern said its resources would not fund operating expenses and capital requirements for 12 months from the report date, raising substantial doubt about its ability to continue as a going concern without substantial additional funding.
The September offering generated approximately $4.0 million gross before about $393,000 of offering expenses. Lantern also accrued $2.0 million for a proposed settlement with a former part-time consultant; the agreement was not finalized or effective. Panna Sharma resigned as President and Chief Executive Officer and director effective November 15, 2026; Chief Financial Officer David Margrave became interim CEO November 16.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointNine-month net loss narrowed to $9.7 million from $13.0 million.
- Moderate pointNine-month operating cash use: $10.1 million versus $12.9 million in 2025.
Negative
- Major pointGoing-concern doubt: current resources will not fund 12 months of operations.
Key Figures
Key Terms
going concern financial
warrant liability financial
pre-funded warrants financial
at-the-market financial
cashless exercised financial
Level 3 inputs financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why does LTRN report substantial doubt about continuing as a going concern?
How much did LTRN raise in its September 2026 offering?
What are the proposed payment terms for Lantern Pharma’s $2 million settlement?
How many shares did LTRN issue from September pre-funded warrants after the quarter ended?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
For
the quarterly period ended
OR
(Exact name of registrant as specified in its charter)
| (State or Other Jurisdiction | (Commission | (IRS Employer | ||
| of Incorporation) | File Number) | Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act: Common Stock
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||
| The
|
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ | ||
| ☒ | Smaller reporting company | ||||
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
As
of November 9, 2026 the registrant had
Table of Contents
| Page | ||
| Forward Looking Statements | ii | |
| PART I – FINANCIAL INFORMATION | ||
| Item 1. | Financial Statements. | 1 |
| Condensed Consolidated Balance Sheets as of September 30, 2026 (unaudited) and December 31, 2025 | 1 | |
| Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2026 and 2025 (unaudited) | 2 | |
| Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2026 and 2025 (unaudited) | 3 | |
| Condensed Consolidated Statements of Changes in Stockholders’ (Deficit) Equity for the three and nine months ended September 30, 2026 and 2025 (unaudited) | 4 | |
| Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2026 and 2025 (unaudited) | 6 | |
| Notes to Condensed Consolidated Financial Statements (unaudited) | 7 | |
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations. | 21 |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk. | 31 |
| Item 4. | Controls and Procedures. | 31 |
| PART II – OTHER INFORMATION | ||
| Item 1A. | Risk Factors. | 32 |
| Item 5. | Other Information. | 33 |
| Item 6. | Exhibits. | 34 |
| Signatures | 35 | |
| i |
FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act, Section 21E of the Securities Exchange Act of 1934, as amended, and other federal securities laws. All statements, other than statements of historical fact, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future preclinical study activities, future clinical trial activities, future research activities, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “model”, “objective”, “aim,” “upcoming”, “should,” ‘will” “would,” or the negative of these words or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties.
The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements relating to:
| ● | the existence of substantial doubt regarding our ability to continue as a going concern in the absence of obtaining substantial additional funding; | |
| ● | our ability to secure sufficient funding and alternative sources of funding to support our existing and proposed preclinical studies and clinical trials; | |
| ● | the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; | |
| ● | our strategic plans to advance the development of any of our drug candidates; | |
| ● | our strategic plans to expand the number of data points that our RADR® platform can access and analyze; | |
| ● | our strategic plans to advance our Open-Medicine AI platform; | |
| ● | our research and development efforts of our internal drug discovery and development programs and antibody drug conjugate (ADC) development program and the utilization of our RADR® platform to streamline the drug development process; | |
| ● | the initiation, timing, progress, and results of our preclinical studies or clinical trials for any of our drug candidates; | |
| ● | our intention to leverage artificial intelligence, machine learning and biomarker data to streamline the drug development process and to identify patient populations that would likely respond to a drug candidate; | |
| ● | our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others; | |
| ● | our expectations regarding our ability to fund our operating expenses and capital expenditure requirements with our existing cash, cash equivalents and marketable securities; | |
| ● | our estimates regarding the potential market opportunity for our drug candidates we or any of our collaborators may in the future develop; | |
| ● | our anticipated growth strategies and our ability to manage the expansion of our business operations effectively; | |
| ● | our expectations related to future expenses and expenditures; | |
| ● | our ability to keep up with rapidly changing technologies and evolving industry standards, including our ability to achieve technological advances; |
| ii |
| ● | our ability to source our needs for skilled labor in the fields of artificial intelligence, genomics, biology, oncology and drug development; and | |
| ● | the impact of government laws and regulations on the development and commercialization of our drug candidates and other operations. |
We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Quarterly Report on Form 10-Q and in the Risk Factors section of our Annual Report on Form 10-K (“2025 Form 10-K”), for the year ended December 31, 2025 filed with the Securities and Exchange Commission, or the SEC, on March 30, 2026, and have identified other factors such as the results of our clinical trials, and the impact of competition, that we believe could cause actual results or events to differ materially from the forward-statements that we make. Furthermore, we operate in a competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report on Form 10-Q.
You should read this Quarterly Report on Form 10-Q and the documents that we file with the SEC with the understanding that our actual future results may be materially different from what we expect. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed elsewhere in this Quarterly Report on Form 10-Q and those listed under the Risk Factors section of our 2025 Form 10-K. You may access our 2025 Form 10-K under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC’s website at www.sec.gov. Given these uncertainties, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this Quarterly Report on Form 10-Q are made as of the date of this Quarterly Report, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
In May 2026, we announced plans to create an independent business entity composed of the AI platform, withZeta.ai, and related technologies and personnel. In July 2026, we formed Open Medicine AI Inc. (“Open Medicine AI”) as a wholly-owned subsidiary to commercialize and expand the multi-agent AI co-scientist platform originally launched as withZeta.ai. In connection with the formation of Open Medicine AI, we entered into asset contribution and license agreements granting Open Medicine AI access to Lantern’s withZeta.ai-related models, data, algorithms, and other assets. The Open-Medicine AI multi-agentic co-scientist platform represents the strategic evolution of withZeta.ai, including the planned expansion into additional disease areas and modalities.
We believe that establishing Open Medicine AI as a separate business entity will facilitate access to dedicated funding sources and potentially allow realization of valuation opportunities separate from our primary drug development operations, and we anticipate Open Medicine AI will become a newly listed company on a national stock exchange or market. However, there can be no assurance that we will be successful in advancing and obtaining funding for the new entity and there can be no assurance that Open Medicine AI will realize commercial success. Our Open-Medicine AI platform is in its early stage of commercial development and is subject to all of the risks of a new start-up business activity.
In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.
Unless the context requires otherwise, references to the “Company,” “Lantern,” “we,” “us,” and “our” in this Quarterly Report on Form 10-Q refer to Lantern Pharma Inc., a Delaware corporation, and, where appropriate, its wholly-owned subsidiaries.
| iii |
PART I – FINANCIAL INFORMATION
Item 1. Financial Statements.
Lantern Pharma Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
| September 30, 2026 | December 31, 2025 | |||||||
| (Unaudited) | ||||||||
| CURRENT ASSETS | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Marketable securities | ||||||||
| Prepaid expenses & other current assets | ||||||||
| Total current assets | ||||||||
| Property and equipment, net | ||||||||
| Operating lease right-of-use assets | ||||||||
| Deferred offering costs | ||||||||
| Other assets | ||||||||
| TOTAL ASSETS | $ | $ | ||||||
| CURRENT LIABILITIES | ||||||||
| Accounts payable and accrued expenses | $ | $ | ||||||
| Operating lease liabilities, current | ||||||||
| Total current liabilities | ||||||||
| Operating lease liabilities, net of current portion | - | |||||||
| Warrant liability | - | |||||||
| TOTAL LIABILITIES | ||||||||
| COMMITMENTS AND CONTINGENCIES (NOTE 4) | - | - | ||||||
| STOCKHOLDERS’ EQUITY | ||||||||
| Preferred Stock ( | - | - | ||||||
| Common Stock ( | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated other comprehensive (loss) income | ( | ) | ||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total stockholders’ equity | ||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | $ | ||||||
See accompanying Notes to Condensed Consolidated Financial Statements
| 1 |
Lantern Pharma Inc. and Subsidiaries
Condensed Consolidated Statements of Operations (Unaudited)
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
Three Months Ended
September 30, | Nine Months Ended
September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| General and administrative | $ | $ | $ | $ | ||||||||||||
| Research and development | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Loss from operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Interest income | ||||||||||||||||
| Other income, net | ||||||||||||||||
| Loss on issuance of warrants | - | - | ( | ) | - | |||||||||||
| Warrant issuance costs | - | - | ( | ) | - | |||||||||||
| Change in fair value of warrant liability | - | - | ||||||||||||||
| NET INCOME (LOSS) | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
| Earnings (loss) per share of common shares, basic | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
| Weighted-average number of common shares outstanding, basic | ||||||||||||||||
| Net loss per share of common stock, diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted-average number of common shares outstanding, diluted | ||||||||||||||||
See accompanying Notes to Condensed Consolidated Financial Statements
| 2 |
Lantern Pharma Inc. and Subsidiaries
Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
Three Months Ended
September 30, | Nine Months Ended
September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| NET INCOME (LOSS) | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
| Other comprehensive loss | ||||||||||||||||
| Unrealized gain (loss) on available-for-sale securities | ( | ) | ( | ) | ( | ) | ||||||||||
| Unrealized loss on foreign currency translation | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other comprehensive loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Comprehensive income (loss) | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
See accompanying Notes to Condensed Consolidated Financial Statements
| 3 |
Lantern Pharma Inc. and Subsidiaries
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) (Unaudited)
Three and Nine Months Ended September 30, 2025
| of Shares | Amount | of Shares | Amount | Capital | Income | Deficit | Equity | |||||||||||||||||||||||||
Preferred
Stock
Number | Preferred
Stock | Common
Stock
Number | Common
Stock | Additional
Paid-in- | Accumulated
Other
Comprehensive | Accumulated | Total
Stockholders’ | |||||||||||||||||||||||||
| of Shares | Amount | of Shares | Amount | Capital | Income | Deficit | Equity | |||||||||||||||||||||||||
| Balance, December 31, 2024 | - | $ | - | $ | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||
| Stock-based compensation | - | - | - | - | - | - | ||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||
| Other comprehensive loss | - | - | - | - | - | ( | ) | - | ( | ) | ||||||||||||||||||||||
| Balance, March 31, 2025 | - | - | ( | ) | ||||||||||||||||||||||||||||
| Stock-based compensation | - | - | - | - | - | - | ||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||
| Other comprehensive loss | - | - | - | - | - | ( | ) | - | ( | ) | ||||||||||||||||||||||
| Balance, June 30, 2025 | - | - | $ | ( | ) | |||||||||||||||||||||||||||
| Stock-based compensation | - | - | - | - | - | - | ||||||||||||||||||||||||||
| Proceeds from the exercise of stock options | - | - | - | - | ||||||||||||||||||||||||||||
| Issuance of common stock for services | - | - | - | - | ||||||||||||||||||||||||||||
| Net proceeds from issuance of common stock, net of issuance costs of $ | - | - | - | - | ||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||
| Other comprehensive loss | - | - | - | - | - | ( | ) | - | ( | ) | ||||||||||||||||||||||
| Balance, September 30, 2025 | - | $ | - | $ | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||
| 4 |
Three and Nine Months Ended September 30, 2026
Preferred
Stock Number | Preferred
Stock | Common
Stock
Number | Common
Stock | Additional
Paid-in- | Accumulated
Other
Comprehensive | Accumulated | Total
Stockholders’
Equity | |||||||||||||||||||||||||
| of Shares | Amount | of Shares | Amount | Capital | Income (Loss) | Deficit | (Deficit) | |||||||||||||||||||||||||
| Balance, December 31, 2025 | - | $ | - | $ | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||
| Vesting of restricted common stock issued for services | - | - | - | |||||||||||||||||||||||||||||
| Stock-based compensation | - | - | - | - | - | - | ||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||
| Other comprehensive loss | - | - | - | - | - | ( | ) | - | ( | ) | ||||||||||||||||||||||
| Balance, March 31, 2026 | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||
| Stock-based compensation | - | - | - | - | - | - | ||||||||||||||||||||||||||
| Issuance of common stock in May 2026 Offering, net of proceeds allocated to warrants | - | - | - | - | - | |||||||||||||||||||||||||||
| Issuance of restricted common stock for services | - | - | - | - | ||||||||||||||||||||||||||||
| Issuance of common stock upon exercise of stock options | - | - | - | - | - | |||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||
| Other comprehensive loss | - | - | - | - | - | ( | ) | - | ( | ) | ||||||||||||||||||||||
| Balance, June 30, 2026 | - | - | $ | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||
| Stock-based compensation | - | - | - | - | - | - | ||||||||||||||||||||||||||
| Issuance of common stock and warrants in September 2026 Offering, net of issuance costs | - | - | - | - | ||||||||||||||||||||||||||||
| Issuance of restricted common stock for services | - | - | - | - | ||||||||||||||||||||||||||||
| Issuance of common stock upon cashless exercise of prefunded warrants | - | - | ( | ) | - | - | - | |||||||||||||||||||||||||
| Net income | - | - | - | - | - | - | ||||||||||||||||||||||||||
| Net income (loss) | - | - | - | - | - | - | ||||||||||||||||||||||||||
| Other comprehensive loss | - | - | - | - | - | ( | ) | - | ( | ) | ||||||||||||||||||||||
| Balance, September 30, 2026 | - | $ | - | $ | $ | $ | ( | ) | $ | ( | ) | $ | ||||||||||||||||||||
See accompanying Notes to Condensed Consolidated Financial Statements
| 5 |
Lantern Pharma Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows (Unaudited)
| 2026 | 2025 | |||||||
Nine Months Ended
September 30, | ||||||||
| 2026 | 2025 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to cash used in operating activities: | ||||||||
| Depreciation and amortization | ||||||||
| Non-cash lease adjustments | ||||||||
| Vesting of restricted common stock issued for services | ||||||||
| Stock-based compensation | ||||||||
| Write-off of deferred offering costs | - | |||||||
| Accretion of discounts on available for sale debt securities, net | ( | ) | ( | ) | ||||
| Loss on issuance of warrants | - | |||||||
| Warrant issuance costs | - | |||||||
| Change in fair value of warrant liability | ( | ) | - | |||||
| Foreign currency remeasurement gain | ( | ) | ( | ) | ||||
| Realized gain on redemptions of available for sale debt securities | - | ( | ) | |||||
| Realized loss on redemption of equity securities | ||||||||
| Unrealized loss (gain) on equity securities | ( | ) | ||||||
| Changes in assets and liabilities: | ||||||||
| Prepaid expenses and other current assets | ( | ) | ||||||
| Accounts payable and accrued expenses | ( | ) | ||||||
| Operating lease liabilities | ( | ) | ( | ) | ||||
| Other assets | - | |||||||
| Net cash flows used in operating activities | ( | ) | ( | ) | ||||
| INVESTING ACTIVITIES | ||||||||
| Purchase of property and equipment | - | ( | ) | |||||
| Purchases of marketable securities | - | ( | ) | |||||
| Redemptions of marketable securities | ||||||||
| Net cash flows provided by investing activities | ||||||||
| FINANCING ACTIVITIES | ||||||||
| Net proceeds from the issuance of common stock, net of issuance costs of $ | - | |||||||
| Proceeds from the May 2026 Offering, net of issuance costs | - | |||||||
| Proceeds from the September 2026 Offering, net of issuance costs | - | |||||||
| Proceeds from option exercise | ||||||||
| Net cash flows provided by financing activities | ||||||||
| Effect of foreign exchange rates on cash | ||||||||
| CHANGE IN CASH AND CASH EQUIVALENTS FOR THE PERIOD | ||||||||
| CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD | ||||||||
| CASH AND CASH EQUIVALENTS, END OF PERIOD | $ | $ | ||||||
| Non-cash investing and financing activities: | ||||||||
| Offering costs in accounts payable and accrued expenses | $ | $ | - | |||||
| Deferred offering costs in accounts payable and accrued expenses | - | |||||||
| Remeasurement of operating lease right-of-use asset and related liability | - | |||||||
See accompanying Notes to Condensed Consolidated Financial Statements
| 6 |
NOTES TO FINANCIAL STATEMENTS
Note 1. Organization, Principal Activities, and Basis of Presentation
Lantern Pharma Inc., and its Subsidiaries (collectively, the “Company”) is an artificial intelligence (A.I.) focused company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. The Company’s development portfolio includes three clinical stage oncology focused product candidates and consists of small molecule drug candidates that others have tried, but failed, to develop into an approved commercialized drug, as well as new compounds that it is developing with the assistance of its A.I. platform and its biomarker driven approach. The Company’s A.I. platform, known as RADR®, uses big data analytics (combining molecular data, drug efficacy data, data from historical studies, data from scientific literature, phenotypic data from trials and publications, and mechanistic pathway data) and machine learning. The Company’s data-driven, genomically-targeted and biomarker-driven approach allows it to pursue a transformational drug development strategy that identifies, rescues or develops, and advances potential small molecule drug candidates.
Lantern Pharma Inc. was incorporated under the laws of the state of Texas on November 7, 2013, and thereafter reincorporated in the state of Delaware on January 15, 2020. The Company’s principal operations are located in Texas. The Company formed a wholly owned subsidiary, Lantern Pharma Limited, in the United Kingdom in July 2017, and dissolved this subsidiary in November 2025. In September 2021, the Company formed a wholly owned subsidiary, Lantern Pharma Australia Pty Ltd, in Australia. In January 2023, the Company formed a wholly owned U.S. subsidiary, Starlight Therapeutics Inc. (“Starlight”), to continue with advancing the development of drug candidate LP-184’s central nervous system (CNS) and brain cancer indications. In July 2026, the Company formed a wholly owned U.S. subsidiary, Open Medicine AI Inc. (“Open Medicine AI”), to commercialize and expand its multi-agent AI co-scientist platform.
Since inception, the Company has devoted substantially all its activity to advancing research and development, including efforts in connection with preclinical studies, clinical trials and development of its A.I. platforms. This now includes three lead drug candidates and an Antibody Drug Conjugate (ADC) program directed towards 11 disclosed therapeutic targets:
| ● | LP-300 (Tavocept), which we are advancing in a Phase 2 clinical trial, the Harmonic™ trial, focused on never smokers with advanced non-small cell lung cancer; | |
| ● | LP-184, which has potential for treatment of solid tumors including breast, bladder, lung and pancreatic cancers, and glioblastoma and other CNS cancers. We have completed enrollment in a Phase 1a clinical trial for LP-184. Following the formation of Starlight, the Company now refers to the molecule LP-184, as it is developed in CNS indications, as “STAR-001”; | |
| ● | LP-284, the stereoisomer (enantiomer) of LP-184, is in a Phase 1 clinical trial, and has shown promising in-vitro and in vivo anticancer activity in multiple hematological cancers, which are distinct from the indications targeted by LP-184; and | |
| ● | Our ADC program is focused on developing highly specific ADCs with highly potent drug payloads. |
The Company’s fiscal year ends on December 31 of each calendar year. The accompanying interim condensed consolidated financial statements are unaudited and have been prepared on substantially the same basis as the Company’s annual consolidated financial statements for the fiscal year ended December 31, 2025. In the opinion of the Company’s management, these interim condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair statement of the Company’s financial position, results of operations and cash flows for the periods presented. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from these estimates.
| 7 |
The December 31, 2025 year-end condensed consolidated balance sheet data in the accompanying interim condensed consolidated financial statements was derived from audited consolidated financial statements. These condensed consolidated financial statements and notes do not include all disclosures required by GAAP and should be read in conjunction with the Company’s audited consolidated financial statements as of and for the year ended December 31, 2025 and the notes thereto included in the Company’s Annual Report on Form 10-K, dated March 30, 2026, on file with the Securities and Exchange Commission.
The results of operations and cash flows for the interim periods included in these condensed consolidated financial statements are not necessarily indicative of the results to be expected for any future period or the entire fiscal year.
Any reference in these notes to applicable guidance refers to Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). To date, the Company has operated its business as one segment. The Company’s condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Lantern Pharma Limited (for the quarter and nine month period ended September 30, 2025), Lantern Pharma Australia Pty Ltd., Starlight Therapeutics Inc, and Open Medicine AI Inc. (for the quarter and nine month period ended September 30, 2026). All intercompany balances and transactions have been eliminated in consolidation.
Note 2. Liquidity and Going Concern
The
Company incurred a net loss of approximately $
In
September 2026, the Company completed a registered direct offering of shares of the Company’s common stock and pre-funded warrants
to purchase common stock. The Company received gross proceeds of approximately $
In addition to its existing capital resources, the Company intends to pursue periodic capital raises, including additional potential sales under the ATM, and also pursue collaborations, grant funding and other opportunities to extend the Company’s operating runway. However, the Company’s cash, cash equivalents, and marketable securities on hand as of the date of this report will not allow the Company to fund its operating expenses and capital expenditure requirements under its current level of operations for 12 months from the date of this report. For this reason, there is substantial doubt about the Company’s ability to continue as a going concern in the absence of obtaining substantial additional funding.
The Company’s ability to continue as a going concern is highly contingent on the ability to raise additional capital for ongoing research and development and clinical trials as the Company expects to continue incurring losses for the foreseeable future. If the Company is not able to raise sufficient additional capital when needed, the Company may be required to delay, reduce or eliminate drug development programs and other activities to support extension of its operating runway. The financial statements in this report have been prepared assuming that the Company will continue as a going concern, and do not include any adjustments that may be necessary should the Company be unable to continue as a going concern. The Company has incurred, and it anticipates it will continue to incur, operating losses and generate negative operating cash flows and as such will require substantial additional funding in the near future to continue its research and development activities. These factors raise substantial doubt about the Company’s ability to continue as a going concern in the absence of obtaining substantial additional funding. While the Company plans to pursue periodic capital raises, including additional potential sales under the ATM, as well as potential collaborations, grant funding and other opportunities to extend the Company’s operating runway, no assurance can be given that sufficient funding will be available when needed to allow the Company to continue as a going concern.
| 8 |
Note 3. Summary of Significant Accounting Policies
Use of Estimates and Assumptions
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The significant areas of estimation include determining research and development accruals, the inputs in determining the fair value of equity-based awards and warrants issued, the inputs in determining present value of lease payments, and determining the fair value of marketable securities. Actual results could differ from those estimates.
Foreign Currency
We translate the financial statements of our Australian subsidiary, which has a functional currency of the Australian dollar, to U.S. dollars using month-end exchange rates for assets and liabilities and average exchange rates for income and expenses. Translation gains and losses are recorded in accumulated other comprehensive income (loss) as a component of stockholders’ equity. Gains and losses resulting from foreign currency transactions that are denominated in currencies other than our functional currency (U.S. dollar) are included within other income, net on the consolidated statements of operations.
Risks and Uncertainties
The Company operates in an industry that is subject to intense competition, government regulation and rapid technological change. Operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory, and other risks, including the potential risk of business failure.
Our
marketable securities may be impacted by various risks related to interest rates, market conditions, stock market fluctuations and credit
risk. Our marketable securities that are debt securities have had and may in the future have their market value fluctuate due to rises
or falls in interest rates. While we believe our cash, cash equivalents and marketable securities do not contain excessive risk, we cannot
provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we
maintain significant amounts of cash and cash equivalents at one or more financial institutions that are federally insured. Interest
bearing and non-interest-bearing accounts we hold at these banking institutions are guaranteed by the Federal Deposit Insurance Corporation
(“FDIC”) up to $
We currently rely on foreign third-party manufacturers and service providers in connection with certain aspects of our clinical operations. The U.S. government and persons involved in the Trump administration have made statements and taken certain actions that have led to, and may continue to lead to, changes to U.S. and international trade policies. Although some previously imposed tariffs have recently been struck down, potential new tariffs and the potential escalation of trade disputes with foreign countries could pose a significant risk to our business and could result in higher operating expenses. U.S. policies on tariffs and international trade could also result in fluctuations in interest rates, which could have a negative impact on general economic conditions, on the industry sector in which we operate, and on our business.
Research and Development
Research and development costs are expensed as incurred. These expenses primarily consist of payroll, contractor expenses, research study expenses, costs for manufacturing and supplies, clinical site costs and other costs for the conduct of clinical trials, costs for technical infrastructure on the cloud for the purposes of developing the Company’s A.I. platforms, and other costs for identifying, developing, and testing drug candidates. Development costs incurred by third parties are expensed as the work is performed. Costs to acquire technologies, including licenses, that are utilized in research and development and that have no alternative future use are expensed when incurred.
| 9 |
When accruing clinical expenses, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If possible, we obtain information regarding unbilled services directly from our service providers. However, we may be required to estimate the cost of these services based only on information available to us. If we underestimate or overestimate the cost associated with a trial or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, our estimated accrued clinical expenses have generally approximated actual expense incurred.
Cash and Cash Equivalents
The
Company considers money market funds and other highly liquid instruments with an original maturity of 3 months or less to be cash equivalents.
Cash equivalents at September 30, 2026 and December 31, 2025 were approximately $
Prepaid Expenses and Other Current Assets
Prepaid
expenses and other current assets as of September 30, 2026 totaled approximately $
Prepaid
expenses and other current assets as of December 31, 2025 totaled approximately $
Leases
The Company determines whether an arrangement contains a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of operating lease liabilities, and net of current portion of operating lease liabilities on our consolidated balance sheets. Lease ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Lease ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. As the Company’s leases do not provide an implicit rate, an incremental borrowing rate is used based on the information available at the commencement date in determining the present value of lease payments. The Company does not include options to extend or terminate the lease term unless it is reasonably certain that the Company will exercise any such options. Rent expense is recognized under the operating leases on a straight-line basis. The Company does not recognize right-of-use assets or lease liabilities for short-term leases, which have a lease term of twelve months or less, and instead will recognize lease payments as expense on a straight-line basis over the lease term.
Marketable Securities
The Company’s marketable securities at September 30, 2026 consist of mutual funds and common stock. The Company’s marketable securities at December 31, 2025 consist of government and agency securities, mutual funds and common stock. We classify our government and agency securities as available-for-sale at the time of purchase, unless they are highly liquid instruments with an original maturity of three months or less, in which case we classify them as cash equivalents. We reevaluate such classification as of each balance sheet date. We may sell these securities at any time for use in current operations even if they have not yet reached maturity. As a result, we classify our investments, including securities with maturities beyond twelve months, as current assets in the accompanying condensed consolidated balance sheets.
| 10 |
Available-for-sale debt securities are recorded at fair value each reporting period. Unrealized gains and losses on available-for-sale debt securities are excluded from earnings and recorded as a separate component within accumulated other comprehensive income (loss) on the condensed consolidated balance sheets until realized. Interest is reported within interest income on the condensed consolidated statements of operations. We evaluate our available-for-sale debt securities to assess whether the amortized cost basis is in excess of estimated fair value and determine what amount of that difference, if any, is caused by expected credit losses. Credit losses are recognized as a charge in other income, net on the condensed consolidated statements of operations, and any remaining unrealized losses are included in accumulated other comprehensive income (loss) on the condensed consolidated balance sheets. The allowance for credit losses is zero at September 30, 2026 and December 31, 2025, and there were no credit losses recorded during the three and nine months ended September 30, 2026 and 2025.
Equity securities, which are composed of mutual funds and common stock, are recorded at fair value each reporting period, with changes in fair value of these investments, as well as dividends earned, recorded within other income, net on the condensed consolidated statements of operations.
We determine realized gains and losses on the sale of marketable securities based on the specific identification method and record such gains and losses within other income, net on the condensed consolidated statements of operations.
Deferred Offering Costs
Deferred
offering costs consist of legal, accounting, underwriting, and other direct costs incurred in connection with the Company’s ATM
financing activities. These costs are capitalized as incurred and recognized as a reduction of additional paid-in capital in the consolidated
statements of stockholders’ equity when shares are issued. At September 30, 2026 and December 31, 2025, the Company had approximately
$
Warrants
The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial instruments and meet all of the requirements for equity classification, including whether the warrants are indexed to the Company’s own shares of common stock, among other conditions for equity classification. This assessment is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are recorded as a reduction in proceeds from the offering at their initial fair value on the date of issuance and remeasured at each balance sheet date thereafter until settlement. Changes in the fair value of liability-classified warrants are recorded as non-cash expense or non-cash income.
The Company’s common stock purchase warrants do not trade in an active securities market, and as such, the Company estimates the fair value of these warrants using a combination of Black Scholes and Monte Carlo pricing models with the assumptions as follows: The risk-free interest rate for periods within the contractual life of the warrant is based on the U.S. Treasury yield curve. The expected life of the warrants is based upon the contractual life of the warrants. The volatility is estimated based on historical volatility of the Company’s stock using the closing price of its common shares. For liability-classified warrants, the key component in the value of the warrant liability is the Company’s stock price, which is subject to significant fluctuation and is not under the Company’s control. The resulting effect on the Company’s net loss or net income is therefore subject to significant fluctuation and will continue to be so until the warrants are exercised, amended or expire. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when the stock price increases and non-cash income when the stock price decreases.
| 11 |
Stock-based Compensation
Stock-based awards have been accounted for as required by ASC 718 Compensation - Stock Compensation. Under ASC 718, awards are valued at fair value on the date of grant, and that fair value is recognized over the requisite service period. Forfeitures are accounted for as they occur.
New Accounting Pronouncements Not Yet Adopted
In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, requiring public business entities to provide disaggregated disclosures of relevant income statement expenses. The amendments aim to improve financial reporting by enhancing transparency in the notes to financial statements, specifically regarding expense categories. The amendments in this update are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The Company is assessing the effect of this update on its consolidated financial statements and related disclosures.
Note 4. Commitments and Contingencies
Accrual Regarding Proposed Settlement
Although
the Proposed Settlement is not yet finalized and is not yet effective, the Company believes the terms of the Proposed Settlement are the
best estimate of loss with respect to this matter, and the Company has accrued $
General
The Company has entered into, and expects to enter into from time to time in the future, license agreements, strategic alliance agreements, assignment agreements, research service agreements, and similar agreements related to the advancement of its product candidates and research and development efforts. Significant agreements (collectively, the “License, Strategic Alliance, and Research Agreements”) are described in detail in the Company’s 2025 Form 10-K. While specific amounts will fluctuate from quarter to quarter based on clinical trials progress, advancement and completion of research studies and manufacturing projects, and other factors, the Company believes its overall activities regarding License, Strategic Alliance, and Research Agreements are materially consistent with those described in the 2025 Form 10-K, as supplemented by the discussion in the following paragraph.
In addition to the specific agreements described in the 2025 Form 10-K, the Company has entered into, and will in the future enter into, other research and service provider agreements for the advancement of its product candidates and research and development efforts. The Company expects to pay additional amounts in future periods in connection with existing and future research and service provider agreements.
Set forth below are the approximate amounts expensed for License, Strategic Alliance, and Research Agreements during the three and nine months ended September 30, 2026 and 2025, respectively. These expensed amounts are included under research and development expenses in the accompanying condensed consolidated statements of operations.
Schedule of Research and Development
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
Three Months Ended
September 30, | Nine Months Ended
September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Amount Expensed for License, Strategic Alliance, and Research Agreements | $ | $ | $ | $ | ||||||||||||
Set forth below at September 30, 2026 and December 31, 2025, respectively, are (1) the approximate amounts accrued and payable under License, Strategic Alliance, and Research Agreements, and (2) the approximate amount of prepaid expenses and other current assets under License, Strategic Alliance, and Research Agreements. These amounts are included in the accompanying condensed consolidated balance sheets.
Schedule of Accounts Payable and Accrued Liabilities
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Amount accrued and payable under License, Strategic Alliance, and Research Agreements | $ | $ | ||||||
| Prepaid expenses and other current assets under License, Strategic Alliance, and Research Agreements | $ | $ | ||||||
| 12 |
Actuate Therapeutics
In
May 2021, the Company entered into a Collaboration Agreement with Actuate Therapeutics, Inc. (“Actuate”), a clinical stage
private biopharmaceutical company focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases
leading to fibrosis. Pursuant to the agreement, the Company and Actuate have collaborated on utilization of the Company’s RADR®
platform to develop novel biomarker derived signatures for use with one of Actuate’s product candidates. As part of the collaboration,
the Company received
In
August 2024, Actuate announced the closing of its initial public offering (“IPO”), which also included a reverse stock split.
Following the reverse stock split and the IPO, the Company holds
Note 5. Leases
The following provides balance sheet information related to leases as of September 30, 2026 and December 31, 2025:
Schedule of Balance Sheet Information Related to Leases
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Assets | ||||||||
| Operating lease, right-of-use asset, net | $ | $ | ||||||
| Liabilities | ||||||||
| Current portion of operating lease liabilities | $ | $ | ||||||
| Operating lease liabilities, net of current portion | - | |||||||
| Total operating lease liabilities | $ | $ | ||||||
At September 30, 2026, the future estimated minimum lease payments under non-cancelable operating leases are as follows:
Schedule of Future Estimated Minimum Lease Payments Under Non-cancelable Operating Leases
| 2026 (remaining three months) | $ | |||
| 2027 | ||||
| Total minimum lease payments | ||||
| Less amount representing interest | ( | ) | ||
| Present value of future minimum lease payments | ||||
| Less current portion of operating lease liabilities | ( | ) | ||
| Operating lease liabilities, net of current portion | $ |
At
September 30, 2026 and December 31, 2025, the Company has two non-cancelable operating leases for office space in Atlanta, Georgia that
require aggregate monthly payments of $
| 13 |
The following table provides a reconciliation for the Company’s right of use assets and lease liabilities:
Schedule of Reconciliation of Right-of-Use Assets and lease Liabilities
| Operating | Operating | |||||||
| Right-of- Use | Lease | |||||||
| Assets | Liabilities | |||||||
| Balance at December 31, 2025 | $ | $ | ||||||
| Remeasurement of operating lease right-of-use assets and operating lease liability | ||||||||
| Amortizations and reductions | ( | ) | ( | ) | ||||
| Balance at September 30, 2026 | $ | $ | ||||||
Other supplemental information related to operating leases is as follows:
Schedule of Other Supplemental Information Related to Operating Leases
| 2026 | 2025 | |||||||
As of September 30, | ||||||||
| 2026 | 2025 | |||||||
| Weighted average remaining term of operating leases (in years) | ||||||||
| Weighted average discount rate of operating leases | % | % | ||||||
The
Company also leases office space in the Dallas, Texas area under two leases. One lease is month-to-month, while the other has a contractual
term of one year and ends November 30, 2026. The Company also leases space for material storage and handling under a one-year
The components of lease expense were approximately as follows for the three and nine months ended September 30, 2026 and 2025:
Schedule of Lease Expense
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Operating lease cost | $ | $ | $ | $ | ||||||||||||
| Short-term lease cost | ||||||||||||||||
| Lease expense | $ | $ | $ | $ | ||||||||||||
During
the nine months ended September 30, 2026 and 2025, cash used in operating activities associated with operating leases was approximately
$
Note 6. Stockholders’ Equity
Common Stock
As
of September 30, 2026 and December 31, 2025, the Company had
May 2026 Offering and Private Placement
On
May 12, 2026, the Company entered into a securities purchase agreement with institutional investors, pursuant to which the Company agreed
to issue and sell to such investors in a registered direct offering (i)
| 14 |
The
Company accounts for the May 2026 Placement Agent Warrants and May 2026 Private Placement Warrants as liabilities, due to settlement
features that may be triggered by a fundamental transaction. The estimated fair value of the May 2026 Private Placement Warrants exceeded
the gross proceeds from the May 2026 Offering on the date of issuance, resulting in a loss on warrant issuance of approximately $
Certain
members of our Board of Directors participated in the May 2026 Offering; they purchased an aggregate of
September 2026 Offering and Private Placement
On
September 28, 2026, the Company entered into a securities purchase agreement with an institutional investor, pursuant to which the Company
agreed to issue and sell to such investor in a registered direct offering (i)
The gross proceeds from the September 2026 Offering were allocated to the common stock, the September 2026 Pre-Funded Warrants and the September 2026 Private Placement Warrants using the relative fair value method as follows, with the fair value of the warrants recorded in additional paid-in-capital on the Company’s consolidated balance sheet.
Schedule of Shareholder’s Equity Fair Value
| Fair Value | Percent of Total Value | Amount Allocated | ||||||||||
| Common stock | $ | % | $ | |||||||||
| September 2026 Pre-Funded Warrants | ||||||||||||
| September 2026 Private Placement Warrants | ||||||||||||
| Total | $ | % | $ | |||||||||
The
fair value of the September 2026 Placement Agent Warrants and September 2026 Private Placement Warrants was estimated using a Black Scholes
model with a risk-free rate of
Other Stock Issuances
During
the nine months ended September 30, 2026, the Company issued
| 15 |
The
Company granted
During
the three and nine months ended September 30, 2025, the Company issued and expensed
Warrants
As
discussed above, on May 14, 2026, the Company issued warrants in the May 2026 Offering. The May 2026 Pre-Funded Warrants, which were
immediately exercisable to purchase
On September 30, 2026, the Company issued warrants as part of the September 2026 Offering. The September 2026 Pre-Funded Warrants are immediately exercisable and have no expiration date. The September 2026 Placement Agent Warrants and September 2026 Private Placement Warrants are not exercisable until shareholder approval of the issuance of the common stock issuable upon exercise of the September 2026 Private Placement Warrants is obtained. When and if such approval is obtained, these warrants will be exercisable for a period of five years before expiring.
A summary of warrant activity for the nine months ended September 30, 2026 is presented below:
Schedule of Warrants Activity
| Exercise Price | Warrants Outstanding, December 31, 2025 | 2026 Warrants Issued | 2026 Warrants Exercised | Warrants Outstanding, September 30, 2026 | ||||||||||||||||
| May 2026 Pre-Funded Warrants | $ | - | ( | ) | - | B | ||||||||||||||
| September 2026 Pre-Funded Warrants | - | - | B | |||||||||||||||||
| May 2026 Placement Agent Warrants | - | - | A | |||||||||||||||||
| September 2026 Placement Agent Warrants | - | - | B | |||||||||||||||||
| May 2026 Private Placement Warrants | - | - | A | |||||||||||||||||
| September 2026 Private Placement Warrants | - | - | B | |||||||||||||||||
| $ | (C) | - | ( | ) | ||||||||||||||||
| A | ||
| B | ||
| C |
| 16 |
Options
On
September 19, 2025 (“Effective Date”), the Company’s stockholders approved a one-time stock option repricing (the “Option
Repricing”) for certain previously granted and still outstanding options held by the Company’s employees and directors. Pursuant
to the Option Repricing, stock options granted under the Lantern Pharma Inc. 2018 Equity Incentive Plan between June 15, 2020 and November
4, 2021 with an exercise price between $
A summary of stock option activity under the Plan, during the nine months ended September 30, 2026 is presented below:
Schedule of Stock Option Activity
| Options Outstanding | ||||||||
Number of
Shares | Weighted-
Average Exercise
Price Per Share | |||||||
| Outstanding December 31, 2025 | $ | |||||||
| Granted | ||||||||
| Prior to Option Repricing | ( | ) | ||||||
| Modified due to Option Repricing | ||||||||
| Exercised | ( | ) | ||||||
| Cancelled or expired | ( | ) | ||||||
| Outstanding September 30, 2026 | $ | |||||||
The
weighted average remaining contractual term of options outstanding and exercisable at September 30, 2026 is
Stock-based compensation relating to stock options was as follows for the three and nine months ended September 30, 2026 and 2025:
Schedule of Stock-based Compensation
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| General and administrative | $ | $ | $ | $ | ||||||||||||
| Research and development | ||||||||||||||||
| Total stock-based compensation | $ | $ | $ | $ | ||||||||||||
Note 7. Fair Value Measurements
We determine the fair values of our financial instruments based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value assumes that the transaction to sell the asset or transfer the liability occurs in the principal or most advantageous market for the asset or liability and establishes that the fair value of an asset or liability shall be determined based on the assumptions that market participants would use in pricing the asset or liability. The classification of a financial asset or liability within the hierarchy is based upon the lowest level input that is significant to the fair value measurement. The fair value hierarchy prioritizes the inputs into three levels that may be used to measure fair value:
Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities.
Level 2 - Inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.
Level 3 - Inputs are unobservable inputs based on our assumptions.
| 17 |
Financial Assets
When available, our marketable securities are valued using quoted prices for identical instruments in active markets. If we are unable to value our marketable securities using quoted prices for identical instruments in active markets, we value our investments using broker reports that utilize quoted market prices for comparable instruments. As of September 30, 2026, our U.S. treasury bills were valued through use of quoted prices for comparable instruments in active markets and are classified as Level 2, and our money markets, common stock and mutual funds were valued using quoted prices in active markets for identical assets and are classified as Level 1.
Based on our valuation of our marketable securities, we concluded that they are classified in either Level 1 or Level 2, and we have no financial assets measured using Level 3 inputs. The following table presents information about our assets that are measured at fair value on a recurring basis using the above input categories.
Schedule of Assets are Measured at Fair Value on Recurring Basis
| Description | Total | Level 1 | Level 2 | Level 3 | ||||||||||||
| Fair Value Measurements as of September 30, 2026 | ||||||||||||||||
| Description | Total | Level 1 | Level 2 | Level 3 | ||||||||||||
| United States treasury bills | $ | $ | - | $ | $ | - | ||||||||||
| Money markets | - | - | ||||||||||||||
| Mutual funds – fixed income | - | - | ||||||||||||||
| Mutual funds – alternative investments | - | - | ||||||||||||||
| Common stock | - | - | ||||||||||||||
| Fair value recurring basis | $ | $ | $ | $ | - | |||||||||||
| Included in cash and cash equivalents | $ | |||||||||||||||
| Included in marketable securities | $ |
| ||||||||||||||
Financial Liabilities
During
the nine months ended September 30, 2026, we issued
Schedule of Change in Fair Value of the Warrant Liability
| Description | Total | Level 1 | Level 2 | Level 3 | ||||||||||||
| Fair Value Measurements as of September 30, 2026 | ||||||||||||||||
| Description | Total | Level 1 | Level 2 | Level 3 | ||||||||||||
| Warrant liability | $ | $ | - | $ | - | $ | ||||||||||
The following table summarizes Level 3 activity for the nine months ended September 30, 2026:
Schedule of Fair Value Accounting of Warrant Activity
| Description | Placement Agent Warrants | Private Placement Warrants | Warrant Liability | |||||||||
| Balance, December 31, 2025 | $ | - | $ | - | $ | - | ||||||
| Fair value of warrants at issuance | ||||||||||||
| Change in fair value of warrant liability | ( | ) | ( | ) | ( | ) | ||||||
| Balance, September 30, 2026 | $ | $ | $ | |||||||||
There were no transfers into or out of Level 3 during the periods presented nor were there any realized gains or losses related to the financial liabilities classified as Level 3.
| 18 |
Note 8. Fair Value of Warrants
The May 2026 Placement Agent Warrants and May 2026 Private Placement Warrants were valued using Black Scholes models and Monte Carlo simulations to estimate the fair value of the warrants based on the possible settlement outcomes. For purposes of the Black Scholes models and Monte Carlo simulations, the Company estimated the likelihood of a fundamental transaction to be 15% as of May 14, 2026 (date of issuance) and 25% as of September 30, 2026. A Black Scholes model and a Monte Carlo simulation were used in determining the fair value of the May 2026 Placement Agent Warrants and May 2026 Private Placement Warrants in the event of a fundamental transaction. The impact of this scenario was immaterial to the overall determination of fair value of the May 2026 Placement Agent Warrants and May 2026 Private Placement Warrants. Changes in the estimated likelihood and timing of a fundamental transaction in future periods could have a material impact on the future valuation of these warrants. The following tables summarize the assumptions used in computing the fair value of warrants subject to fair value accounting as of the date of issuance and as of September 30, 2026.
Schedule of Fair Value of Warrants
| May 2026 Placement Agent Warrants | Issued During
the Nine Months Ended September 30, 2026 | As of
September 30, 2026 | ||||||
| Exercise price | $ | $ | ||||||
| Expected life (years) | ||||||||
| Expected volatility | % | % | ||||||
| Risk-free interest rate | % | % | ||||||
| Expected dividend yield | - | % | - | % | ||||
| Share price | $ | $ | ||||||
| May 2026 Private Placement Warrants | Issued During the Nine Months Ended September 30, 2026 | As of
September 30, 2026 | ||||||
| Exercise price | $ | $ | ||||||
| Expected life (years) | ||||||||
| Expected volatility | % | % | ||||||
| Risk-free interest rate | % | % | ||||||
| Expected dividend yield | - | % | - | % | ||||
| Share price | $ | $ | ||||||
Note 9. Earnings (Loss) Per Share
Basic earnings (loss) per share is derived by dividing net income (loss) applicable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings (loss) per share includes the effect, if any, from the potential exercise or conversion of securities, such as warrants and stock options, which would result in the issuance of incremental shares of common stock unless such effect is anti-dilutive.
Schedule of Anti-dilutive Securities Outstanding Diluted Loss Per Share
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Numerator: | ||||||||||||||||
| Net income (loss) for basic earnings per share | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
| Change in fair value of warrant liability | ( | ) | - | ( | ) | - | ||||||||||
| Net loss for diluted earnings per share | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Denominator: | ||||||||||||||||
| Weighted-average basic common shares outstanding | ||||||||||||||||
| Assumed conversion of dilutive securities: | ||||||||||||||||
| Common stock purchase warrants | - | - | ||||||||||||||
| Potentially dilutive common shares | ||||||||||||||||
| Basic earnings (loss) per share | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
| Diluted net loss per share | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| 19 |
Potentially dilutive securities outstanding that have been excluded from diluted earnings (loss) per share due to being anti-dilutive include the following:
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Common stock purchase warrants | - | - | ||||||||||||||
| Stock options | ||||||||||||||||
| Anti-dilutive securities | ||||||||||||||||
The September 2026 Pre-Funded Warrants were included in outstanding shares for purposes of computing basic and diluted earnings (loss) per share for the three and nine months ended September 30, 2026.
Note 10. Segment Reporting
The
Company operates as
Cash, cash equivalents and marketable securities were as follows at September 30, 2026 and December 31, 2025:
Schedule of Segment Reporting Information
September 30, 2026 | December 31, 2025 | |||||||
| Cash | $ | $ | ||||||
| Cash equivalents | ||||||||
| Marketable securities | ||||||||
Research and development study and material costs were as follows during the three and nine months ended September 30, 2026 and 2025:
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Research and development studies | $ | $ | $ | $ | ||||||||||||
| Research and development materials | ||||||||||||||||
| Research and development costs | $ | $ | $ | $ | ||||||||||||
These financial metrics are used by the CODM to make key operating decisions, such as which research and development studies to commence, extend or discontinue. See the condensed consolidated balance sheets as of September 30, 2026 and December 31, 2025, as well as the condensed consolidated statements of operations for the three and nine months ended September 30, 2026 and 2025.
Note 11. Subsequent Events
Resignation of CEO; Appointment of Interim CEO
On November 15, 2026, Panna Sharma resigned as President and Chief Executive Officer of the Company, effective as of November 15, 2026. Mr. Sharma also resigned from the Company’s board of directors (“Board”) effective as of November 15, 2026.
Effective November 16, 2026, the Board has appointed David Margrave, current Chief Financial Officer of the Company, as Interim Chief Executive Officer until the Company appoints a permanent Chief Executive Officer. The Board intends to promptly commence a search for a successor.
Exercise of Pre-Funded Warrants
On
October 26, 2026, a portion of the September 2026 Pre-Funded Warrants was exercised for cash, resulting in the issuance of
| 20 |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
You should read the following discussion and analysis of our financial condition and plan of operations together with our condensed consolidated financial statements and the related notes appearing elsewhere in this Quarterly Report. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from the plans, intentions, expectations and other forward-looking statements included in the discussion below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those factors discussed in the Risk Factors section of our 2025 Form 10-K on file with the SEC.
Overview
We are an artificial intelligence (A.I.) focused company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Our development portfolio includes three clinical stage oncology focused product candidates and consists of small molecules that others have tried, but failed, to develop into an approved commercialized drug, as well as new compounds that we are developing with the assistance of our proprietary A.I. platform and our biomarker driven approach. Our A.I. platform, known as RADR®, currently includes more than 200 billion data points, and uses big data analytics (combining molecular data, drug efficacy data, data from historical studies, data from scientific literature, phenotypic data from trials and publications, and mechanistic pathway data) and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds. This data-driven, genomically-targeted and biomarker-driven approach allows us to pursue a transformational drug development strategy that identifies, rescues or develops, and advances potential small molecule drug candidates at what we believe is a fraction of the time and cost associated with traditional cancer drug development.
We have active clinical programs for our three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple important cancer indications, including both solid tumors and blood cancers. We have established a wholly-owned subsidiary, Starlight Therapeutics, to focus exclusively on the clinical development of our promising opportunities for central nervous system (“CNS”) and brain cancers, many of which have no effective treatment options. We are also advancing an antibody-drug conjugate (“ADC”) program focused on developing highly specific ADCs with highly potent drug-payloads.
In January 2026, we introduced withZeta.ai — a generative AI platform purpose-built to empower researchers and clinicians to accelerate rare cancer research and drug development, dramatically improve research quality, and reduce R&D costs.
Open-Medicine AI
In May 2026, we announced plans to create an independent business entity composed of the AI platform, withZeta.ai, and related technologies and personnel. In July 2026, we formed Open Medicine AI as a wholly-owned subsidiary to commercialize and expand the multi-agent AI co-scientist platform originally launched as withZeta.ai. In connection with the formation of Open Medicine AI, we entered into asset contribution and license agreements granting Open Medicine AI access to Lantern’s withZeta.ai-related models, data, algorithms, and other assets. The Open-Medicine AI multi-agentic co-scientist platform represents the strategic evolution of withZeta.ai, including the planned expansion into additional disease areas and modalities.
Open Medicine AI inherits the full multi-agentic system originally launched as withZeta.ai, including:
| ● | Coordinated specialist agents spanning medicinal chemistry, computational biology, clinical trial strategy, biomarkers & translational science, clinical oncology, and general research. | |
| ● | Three research modes (Explorer, Investigator, Reporter) that support rapid exploration through deep multi-source investigation to structured reporting. | |
| ● | Proprietary rare-cancer knowledge bases and ontologies covering hundreds of disease entities, biomarkers, clinical trials, and literature. | |
| ● | Expanding computational layers, including ZetaOmics™ for multi-omic analysis and continued development of parallel swarm intelligence capabilities. |
| 21 |
While rare cancers and oncology remain core components, Open Medicine AI’s roadmap includes systematic expansion into additional high-need disease areas – especially in collaboration with leading academic and commercial leaders – that experience the same challenges of fragmented knowledge, high failure costs, limited traditional investment and urgency of patient and disease management needs. We believe that the multi-agentic co-scientist capabilities of Open Medicine AI — specialized agents working in coordinated intelligence rather than a single model answering isolated questions — can dramatically compress research timelines and reduce the cost of generating hardened, actionable scientific insights.
Drug Development
Our strategy is to both develop new drug candidates using our RADR® platform, and other machine learning driven methodologies, and to pursue the development of drug candidates that have undergone previous clinical trial testing or that may have been halted in development or deprioritized because of insufficient clinical trial efficacy (i.e., a meaningful treatment benefit relevant for the disease or condition under study as measured against the comparator treatment used in the relevant clinical testing) or for strategic reasons by the owner or development team responsible for the compound. Importantly, these historical drug candidates appear to have been well-tolerated in many instances, and often have considerable data from previous toxicity, tolerability and ADME (absorption, distribution, metabolism, and excretion) studies that have been completed. Additionally, these drug candidates may also have a body of existing data supporting the potential mechanism(s) by which they achieve their intended biologic effect, but often require more targeted trials in a stratified group of patients to demonstrate statistically meaningful results. Our dual approach to both develop de-novo, biomarker-guided drug candidates and “rescue” historical drug-candidates by leveraging A.I., recent advances in genomics, computational biology and cloud computing is emblematic of a new era in drug development that is being driven by data-intensive approaches meant to de-risk development and accelerate the clinical trial process. In this context, we intend to create a diverse portfolio of oncology drug candidates for further development towards regulatory and marketing approval with the objective of establishing a leading A.I.-driven methodology for treating the right patient with the right oncology therapy.
A key component of our strategy is to target specific cancer patient populations and treatment indications identified by leveraging our RADR® platform, a proprietary A.I. enabled engine created and owned by us. We believe the combination of our therapeutic area expertise, our A.I. expertise, and our ability to identify and develop promising drug candidates through our collaborative relationships with research institutions in selected areas of oncology gives us a significant competitive advantage. Our RADR® platform has been developed and refined over the last several years and integrates billions of data points immediately relevant for oncology drug development and patient response prediction using artificial intelligence and proprietary machine learning algorithms. By identifying clinical candidates, together with relevant genomic and phenotypic data, we believe our approach will help us design more efficient pre-clinical studies, and more targeted clinical trials, thereby accelerating our drug candidates’ time to approval and eventually to market. Although we have not yet applied for or received regulatory or marketing approval for any of our drug candidates, we believe our RADR® platform has the ability to reduce the cost and time to bring drug candidates to specifically targeted patient groups. We believe we have developed a sustainable and scalable biopharma business model by combining a unique, oncology-focused big-data platform that leverages artificial intelligence along with active clinical and preclinical programs that are being advanced in targeted cancer therapeutic areas to address today’s treatment needs.
Our current portfolio consists of three lead drug candidates that are in clinical phases (known as LP-300, LP-184 and LP-284) and an Antibody Drug Conjugate (ADC) program that is in preclinical research optimization. In January 2023, we formed a wholly owned subsidiary, Starlight Therapeutics Inc. (“Starlight”), to develop drug candidate LP-184’s central nervous system (CNS) and brain cancer indications – including glioblastoma (GBM), brain metastases (brain mets.), and several rare pediatric CNS cancers. Following the formation of Starlight, we may also refer to the molecule LP-184, as it is developed in CNS indications, as “STAR-001”. All of these drug candidates and our ADC program are leveraging precision oncology, A.I. and genomic driven approaches to accelerate and direct development efforts.
| 22 |
We are conducting a targeted phase 2 trial (the Harmonic™ trial) for LP-300 in never smoking patients with NSCLC in combination with chemotherapy, under an existing investigational new drug application. Based on the successful outcome in May 2026 from a Type C meeting request with the FDA focused on the LP-300 Harmonic™ clinical trial, we are focusing future Harmonic™ enrollment on patients with the EGFR exon 21 L858R mutation, a subtype of tyrosine kinase mutations that demonstrates lower sensitivity and inferior treatment outcome to osimertinib based therapy. Preliminary analysis of Harmonic™ study data suggests that patients with this mutation may derive greater clinical benefit from the LP-300 triplet regimen. Our candidate LP-184 has shown promising in-vitro and in vivo anticancer activity in multiple solid tumor indications (including triple negative breast, lung, bladder, glioblastoma and pancreatic cancer), and enrollment has been completed in a Phase 1a clinical trial for LP-184. Based on the results and insights from the LP-184 Phase 1a clinical trial, we are preparing to commence multiple future LP-184 clinical studies. Our candidate LP-284 has shown promising in-vitro and in vivo anticancer activity in multiple hematological cancers, which are distinct from the indications targeted by LP-184. LP-284 is currently in a Phase 1A clinical trial.
Our ADC program is focused on developing highly specific ADCs with highly potent drug-payloads. We have used our RADR® A.I. platform to advance and refine an A.I. powered module focused on improving the precision, cost and timelines of ADC development for cancer. In 2023, we entered into a research collaboration with Bielefeld University in Germany focused on development of ADCs utilizing cryptophycin as the ADC drug-payload. Cryptophycins are promising antitumor molecules that have demonstrated potency at ultra-low, picomolar, concentrations. In a broad range of preclinical studies, the cryptophycin-ADC synthesized as part of the Bielefeld collaboration demonstrated promising picomolar level potency and anti-tumor activity in multiple solid tumor cell lines, including breast, bladder, colorectal, gastric, pancreatic and ovarian.
In addition to our lead drug candidates and ADC program, we also have an additional drug candidate, LP-100, that we believe has potential for future development in combination with the class of anticancer agents known as PARP inhibitors (PARPi). For LP-100, as well as our lead drug candidate LP-300, we have leveraged data from prior preclinical studies and clinical trials, along with insights generated from our A.I. platform, to target the types of tumors and patient groups we believe will be most responsive to the drug. Both LP-100 and LP-300 showed promise in important patient subgroups, but failed pivotal Phase 3 trials when the overall results did not meet the predefined clinical endpoints. We believe that this was due to a lack of biomarker-driven patient stratification.
LP-300 has been studied in multiple randomized, controlled, multi-center non-small cell lung cancer, or NSCLC, trials that included administration of either paclitaxel and cisplatin and/or docetaxel and cisplatin. LP-100 has previously been in a genomic signature guided phase 2 clinical trial in Denmark for patients with metastatic castration resistant prostate cancer (mCRPC). 9 patients (out of a targeted enrollment of 27) were treated in the trial. The median overall survival (OS) for the initial group of 9 patients was approximately 12.5 months, which is an improvement over other similar fourth-line treatment regimens for mCRPC. Based on our evaluation of the synergies of LP-100 with PARP inhibitors, the decision was made in the first quarter of 2023 to close the phase 2 clinical trial in Denmark, to allow the focus of LP-100-directed resources on positioning the molecule for development in earlier lines of therapy with potentially larger market opportunities. LP-100 was previously out-licensed by us to Allarity Therapeutics A/S. In July 2021, we entered into an Asset Purchase Agreement to reacquire global development and commercialization rights for LP-100 from Allarity.
Our development strategy is to pursue an increasing number of oncology focused, molecularly targeted therapies where artificial intelligence and genomic data can help us provide biological insights, reduce the risk associated with development efforts and help clarify potential patient response. We plan on strategically evaluating these on a program-by-program basis as they advance into clinical development, either to be done entirely by us, or with licensing partners, to maximize the commercial opportunity and reduce the time it takes to bring the right drug to the right patient.
We have incurred net operating losses to date and our operations have been financed primarily by sales of our equity securities. Our net losses were approximately $9,705,000 and $13,045,000 for the nine months ended September 30, 2026 and 2025, respectively.
| 23 |
Our net losses have primarily resulted from costs incurred in licensing and developing the drug candidates in our pipeline, planning, preparing and conducting preclinical studies and clinical testing, and general and administrative activities associated with our operations. We expect to continue to incur significant expenses and corresponding operating losses for the foreseeable future as we continue to advance our pipeline. Our costs may further increase as we conduct additional preclinical studies and clinical trials and potentially seek regulatory clearance for and prepare to commercialize our drug candidates. We expect to incur significant expenses to continue to build the infrastructure necessary to support our operations, preclinical studies, clinical trials, and potential commercialization, including manufacturing, marketing, sales and distribution functions. We have experienced and will continue to experience substantial costs associated with operating as a public company.
Resignation of CEO; Appointment of Interim CEO
On November 15, 2026, Panna Sharma resigned as President and Chief Executive Officer of the Company, effective as of November 15, 2026. Mr. Sharma also resigned from the Company’s board of directors (“Board”) effective as of November 15, 2026.
Effective November 16, 2026, the Board has appointed David Margrave, current Chief Financial Officer of the Company, as Interim Chief Executive Officer until the Company appoints a permanent Chief Executive Officer. The Board intends to promptly commence a search for a successor.
Components of Our Results of Operations
Revenues
We did not recognize revenues for the nine-month periods ended September 30, 2026 and 2025.
Research and Development
Research and development expenses consist primarily of costs incurred for the research and development of our preclinical and clinical candidates, which include:
| ● | expenses incurred towards research and development employees, consultants, outside contractors, laboratories, clinical sites, and investigators that conduct our preclinical or clinical research activities; and | |
| ● | the cost of acquiring and developing preclinical and clinical study materials and lab supplies, including manufacturing costs related to our drug candidates. |
We expense research and development costs to operations as incurred.
Our research and development expenses by project category for the nine months ended September 30, 2026 and 2025 are as follows:
| Nine Months | Nine Months | |||||||
Ended
September 30, 2026 | Ended
September 30, 2025 | |||||||
| LP-300 | $ | 2,087,560 | $ | 3,192,736 | ||||
| LP-184 | 1,570,184 | 3,420,893 | ||||||
| LP-284 | 590,277 | 965,575 | ||||||
| RADR® and Open-Medicine AI* | 620,274 | 801,800 | ||||||
| Other ** | 216,018 | 388,301 | ||||||
| Total research and development expenses | $ | 5,084,313 | $ | 8,769,305 | ||||
| * | Open-Medicine AI expenses relate to 2026 |
| ** | LP-100 and ADC Program expenses are included in “Other.” |
We expect that our research and development expenses will fluctuate from quarter to quarter and year to year. We expect that our research and development expenses will increase substantially over time based on the progress of our clinical trials for LP-300, LP-184 and LP-284, and other programs and drug candidates. We expect to make substantial expenditures associated with research and service provider agreements for the advancement of our drug candidates and research and development efforts.
| 24 |
Because of the numerous risks and uncertainties associated with product development, we cannot determine with certainty the duration and completion costs of these or other current or future clinical trials of LP-300, LP-184, LP-284 or our other drug candidates. We may never succeed in achieving regulatory approval for LP-300, LP-184, LP-284 or any of our other drug candidates. The duration, costs and timing of clinical trials and development of our drug candidates will depend on a variety of factors, including the uncertainties of future clinical and preclinical studies, uncertainties in clinical trial enrollment rates, significant and changing government regulation, and geopolitical risk, including in Taiwan where we are pursuing clinical testing of LP-300. In addition, the probability of success for each drug candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability.
General and Administrative
General and administrative expenses consist primarily of salaries and related costs for employees in executive, finance and administration, corporate development and administrative support functions, including stock-based compensation expenses and benefits. Other significant general and administrative expenses include accounting and legal services, insurance, the cost of various consultants, investor relations, occupancy costs, and information systems costs.
We expect fluctuating and increased administrative costs resulting from our existing and anticipated clinical trials and the potential commercialization of our drug candidates. We believe that these increases will likely include future increased costs for hiring additional administrative personnel to support future market research and future product commercialization efforts and increased fees for outside consultants, attorneys and accountants.
Summary Results of Operations for the Three and Nine Months Ended September 30, 2026 and 2025 (unaudited)
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| General and administrative | $ | 3,809,301 | $ | 1,912,829 | $ | 7,206,907 | $ | 5,006,427 | ||||||||
| Research and development | 1,568,582 | 2,436,971 | 5,084,313 | 8,769,305 | ||||||||||||
| Total operating expenses | 5,377,883 | 4,349,800 | 12,291,220 | 13,775,732 | ||||||||||||
| Loss from operations | (5,377,883 | ) | (4,349,800 | ) | (12,291,220 | ) | (13,775,732 | ) | ||||||||
| Interest income | 26,681 | 100,921 | 98,920 | 365,456 | ||||||||||||
| Other income, net | 3,156 | 71,456 | 51,998 | 365,055 | ||||||||||||
| Loss on issuance of warrants | - | - | (726,427 | ) | - | |||||||||||
| Warrant issuance costs | - | - | (755,233 | ) | - | |||||||||||
| Change in fair value of warrant liability | 6,044,661 | - | 3,917,282 | - | ||||||||||||
| NET INCOME (LOSS) | $ | 696,615 | $ | (4,177,423 | ) | $ | (9,704,680 | ) | $ | (13,045,221 | ) | |||||
Comparison of the Three Months Ended September 30, 2026 and 2025
General and Administrative Expenses
General and administrative expenses increased approximately $1,896,000, or 99%, from approximately $1,913,000 for the three months ended September 30, 2025 to approximately $3,809,000 for the three months ended September 30, 2026. The increase was primarily caused by the accrual of an estimated proposed legal settlement of $2,000,000 during the three months ended September 30, 2026, in addition to increases in salaries and benefit expenses of approximately $129,000, increases in other professional fees of approximately $31,000, and increases in patent costs of approximately $9,000. These increases were partially offset by decreases in business development and investor relations expenditures of approximately $229,000, declines in travel expenditures of approximately $23,000, and a reduction in rent expense of approximately $20,000.
| 25 |
Research and Development Expenses
Research and development expenses decreased approximately $868,000, or 36%, from approximately $2,437,000 for the three months ended September 30, 2025 to approximately $1,569,000 for the three months ended September 30, 2026. The decrease was attributable to reductions in research studies and materials costs of approximately $686,000 relating to the conduct and support of our clinical trials, decreases in salaries and benefit expenses of approximately $177,000, and decreases in consulting expenses of approximately $18,000. These decreases were partially offset by increases in licensing fees of approximately $13,000.
Interest and Other Income, Net
Interest income decreased approximately $74,000, or 74%, from approximately $101,000 for the three months ended September 30, 2025 to approximately $27,000 for the three months ended September 30, 2026. This decrease was primarily due to reductions in the amount of marketable securities held by us during the three months ended September 30, 2026 as compared to the three months ended September 30, 2025. Other income, net decreased approximately $68,000, or 96%, from approximately $71,000 for the three months ended September 30, 2025 to approximately $3,000 for the three months ended September 30, 2026. This decrease was primarily attributable to reductions in dividend income and other investment income of $24,000 and $40,000, respectively, during the three months ended September 30, 2026.
Change in Fair Value of Warrant Liability
During the three months ended September 30, 2026, the estimated fair value of the May 2026 Private Placement Warrants and May 2026 Placement Agent Warrants issued in our May 2026 Offering decreased by approximately $6,045,000 due primarily to a decrease in the Company’s stock price, resulting in a noncash gain.
Comparison of the Nine Months Ended September 30, 2026 and 2025
General and Administrative Expenses
General and administrative expenses increased approximately $2,200,000, or 44%, from approximately $5,006,000 for the nine months ended September 30, 2025 to approximately $7,207,000 for the nine months ended September 30, 2026. The increase was primarily caused by the accrual of an estimated proposed legal settlement of $2,000,000 during the nine months ended September 30, 2026, in addition to increases in salaries and benefit expenses of approximately $337,000, increases in business development and investor relations expenditures of approximately $169,000, and increases in patent costs of approximately $130,000. These increases were partially offset by decreases in other professional fees of approximately $323,000, declines in travel expenditures of approximately $63,000 and a reduction in rent expense of approximately $52,000.
Research and Development Expenses
Research and development expenses decreased approximately $3,685,000, or 42%, from approximately $8,769,000 for the nine months ended September 30, 2025 to approximately $5,084,000 for the nine months ended September 30, 2026. The decrease was attributable to reductions in research studies and materials costs of approximately $3,026,000 relating to the conduct and support of our clinical trials and decreases in salaries and benefit expenses of approximately $708,000. These decreases were partially offset by increases in consulting expenses and licensing fees of approximately $10,000 and $38,000, respectively.
| 26 |
Interest and Other Income, Net
Interest income decreased approximately $267,000 or 73%, from approximately $365,000 for the nine months ended September 30, 2025 to approximately $99,000 for the nine months ended September 30, 2026. This decrease was primarily due to reductions in the amount of marketable securities held by us during the nine months ended September 30, 2026 as compared to the nine months ended September 30, 2025. Other income, net decreased approximately $313,000, or 86%, from approximately $365,000 for the nine months ended September 30, 2025 to approximately $52,000 for the nine months ended September 30, 2026. This decrease was primarily attributable to reductions in dividend income and other investment income of $80,000 and $176,000, respectively, and a decrease in foreign currency gains of approximately $52,000 during the nine months ended September 30, 2026.
Loss on Issuance of Warrants
During the nine months ended September 30, 2026, we issued the May 2026 Private Placement Warrants with an initial fair value of approximately $5,126,000, which exceeded gross proceeds from our Offering (as discussed below), resulting in a non-cash loss on issuance of warrants of approximately $726,000.
Warrant Issuance Costs
During the nine months ended September 30, 2026, we incurred approximately $755,000 of warrant issuance costs, which includes the estimated grant date fair value of approximately $243,000 relating to the May 2026 Placement Agent Warrants issued to our placement agent as part of our May 2026 Offering.
Change in Fair Value of Warrant Liability
During the nine months ended September 30, 2026, the estimated fair value of the May 2026 Private Placement Warrants and May 2026 Placement Agent Warrants issued in our May 2026 Offering decreased by approximately $3,917,000 due primarily to a decrease in the Company’s stock price between the date of issuance and September 30, 2026, resulting in a noncash gain.
Cash Flows
The following table summarizes our cash flow for the periods indicated:
For the Nine Months
Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| (Unaudited) | ||||||||
| Net cash flows used in operating activities | $ | (10,054,406 | ) | $ | (12,884,867 | ) | ||
| Net cash flows provided by investing activities | 5,614,287 | 12,761,027 | ||||||
| Net cash flows provided by financing activities | 7,616,781 | 971,781 | ||||||
| Effect of foreign exchange rates on cash | 16,313 | 30,466 | ||||||
| Net increase in cash and cash equivalents | $ | 3,192,975 | $ | 878,407 | ||||
Operating Activities
For the nine months ended September 30, 2026, net cash used in operating activities was approximately $10,054,000 compared to approximately $12,885,000 for the nine months ended September 30, 2025. The primary cause of the reduction in cash used in operating activities is a decrease in net loss of approximately $1,703,000 (after adjustments for noncash and non-operating cash flows included in net loss) during the nine months ended September 30, 2026 when compared to the nine months ended September 30, 2025. Accounts payable and accrued expenses also increased by approximately $1,071,000 during the nine months ended September 30, 2026 compared to a decrease of approximately $195,000 during the nine months ended September 30, 2025, resulting in less cash outflows.
| 27 |
Investing Activities
For the nine months ended September 30, 2026, net cash provided by investing activities was approximately $5,614,000 compared to approximately $12,761,000 of net cash provided by investing activities for the nine months ended September 30, 2025. The decrease in cash provided by investing activities is due to a decrease in net redemptions of investments in marketable securities during the nine months ended September 30, 2026, as compared to the nine months ended September 30, 2025.
Financing Activities
For the nine months ended September 30, 2026, net cash provided by financing activities was approximately $7,617,000 compared to approximately $972,000 of net cash provided by financing activities for the nine months ended September 30, 2025. The increase in cash provided by financing activities is attributable primarily to net proceeds received in the May 2026 Offering and September 2026 Offering.
Operating Capital and Capital Expenditure Requirements
As of September 30, 2026, we had total assets of approximately $8,525,000 and working capital of approximately $2,759,000. As of September 30, 2026, our liquidity included approximately $7,627,000 of cash, cash equivalents and marketable securities. In July 2025, we entered into the ATM with ThinkEquity, as sales agent, pursuant to which we may offer and sell shares of our common stock from time to time, in “at-the-market” offerings to or through our sales agent. No sales were made under the ATM during the nine months ended September 30, 2026.
On May 12, 2026, we entered into a securities purchase agreement with institutional investors, pursuant to which we agreed to issue and sell to such investors in a registered direct offering (i) 1,454,175 shares of common stock of the Company, at an offering price of $2.06 per share, and (ii) pre-funded warrants to purchase up to 681,748 shares of common stock in lieu of the common shares, at an offering price of $2.0599 (such registered direct offering, the “May 2026 Offering”). The May 2026 Offering closed on May 14, 2026, and we received gross proceeds of approximately $4,400,000 from the offering, before deducting offering expenses payable by us of approximately $512,000. In addition, in a concurrent private placement, we agreed to issue to such investors warrants to purchase up to 2,135,923 shares of common stock, at an exercise price of $2.27 per share.
On September 28, 2026, the Company entered into a securities purchase agreement with an institutional investor, pursuant to which the Company agreed to issue and sell to such investor in a registered direct offering (i) 1,469,725 shares of common stock of the Company, at an offering price of $1.09 per share, and (ii) pre-funded warrants to purchase up to 2,200,000 shares of common stock in lieu of the common shares, at an offering price of $1.0899 per share (such registered direct offering, the “September 2026 Offering”). The September 2026 Offering closed on September 30, 2026, and the Company received gross proceeds of approximately $4,000,000, before deducting offering expenses payable by the Company of approximately $393,000. In a concurrent private placement, the Company agreed to issue, to such investor, warrants to purchase up to 3,669,725 shares of common stock, at an exercise price of $1.09 per share.
In addition to our existing capital resources, we intend to pursue periodic capital raises, including additional potential sales under the ATM, and also pursue collaborations, grant funding and other opportunities to extend our operating runway. However, our cash, cash equivalents, and marketable securities on hand as of the date of this report will not allow us to fund our operating expenses and capital expenditure requirements under our current level of operations for 12 months from the date of this report. For this reason, there is substantial doubt about our ability to continue as a going concern in the absence of obtaining substantial additional funding.
| 28 |
Our ability to continue as a going concern is highly contingent on the ability to raise additional capital for ongoing research and development and clinical trials as we expect to continue incurring losses for the foreseeable future. If we are not able to raise sufficient additional capital when needed, we may be required to delay, reduce or eliminate drug development programs and other activities to support extension of our operating runway. The financial statements in this report have been prepared assuming that we will continue as a going concern, and do not include any adjustments that may be necessary should we be unable to continue as a going concern. We have incurred, and anticipate that we will continue to incur, operating losses and generate negative operating cash flows and as such will require substantial additional funding in the near future to continue our research and development activities. These factors raise substantial doubt about our ability to continue as a going concern in the absence of obtaining substantial additional funding. While we plan to pursue periodic capital raises, including additional potential sales under the ATM, as well as potential collaborations, grant funding and other opportunities to extend our operating runway, no assurance can be given that sufficient funding will be available when needed to allow us to continue as a going concern.
We expect to incur significant, fluctuating and often increasing operating losses at least for the next several years as we continue our clinical development of LP-300, LP-184 and LP-284, pursue development of our other drug candidates and programs, and seek potential future marketing approval for our drug candidates, which could be several years in the future, if at all. We do not expect to generate revenue, other than anticipated revenue from Open Medicine AI and possible license and grant revenue, unless and until we successfully complete development and obtain regulatory approval for our therapeutic candidates. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our existing and planned clinical trials and our expenditures on other research and development activities.
We have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all of our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. We anticipate that our expenses will fluctuate and may increase substantially as we:
| ● | continue the development, including preclinical studies and clinical trials, of our drug candidates; | |
| ● | initiate preclinical studies and clinical trials for any additional indications for our current drug candidates and any future drug candidates that we may pursue; | |
| ● | continue to build our portfolio of drug candidates through the acquisition or in-license of additional drug candidates or technologies; | |
| ● | continue to develop, maintain, expand and protect our intellectual property portfolio; | |
| ● | pursue regulatory approvals for those of our current and future drug candidates that successfully complete clinical trials; | |
| ● | ultimately establish a sales, marketing, distribution and other commercial infrastructure to commercialize any drug candidate for which we may obtain marketing approval; | |
| ● | hire additional clinical, regulatory, scientific and accounting personnel; | |
| ● | incur additional legal, accounting and other expenses in operating as a public company; and | |
| ● | continue to develop, maintain, and expand our RADR® platform and AI and machine learning technologies. |
We expect that we will need to obtain substantial additional funding in order to complete our clinical trials. To the extent that we raise additional capital through the sale of common stock, convertible securities or other equity securities, the ownership interests of our existing stockholders may be materially diluted and the terms of these securities could include liquidation or other preferences that could adversely affect the rights of our existing stockholders. In addition, debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business. If we are unable to raise capital when needed or on attractive terms, we could be forced to significantly delay, scale back or discontinue the development or commercialization of LP-300, LP-184, LP-284, and/or other drug candidates and programs, seek collaborators at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available, and relinquish or license, potentially on unfavorable terms, our rights to LP-300, LP-184, LP-284, and/or other drug candidates and programs that we otherwise would seek to develop or commercialize ourselves.
| 29 |
Critical Accounting Estimates
We prepare our consolidated financial statements in accordance with generally accepted accounting standards in the United States of America. Our significant accounting policies are described in Note 3 to our consolidated financial statements included as part of this report. Critical accounting policies and significant accounting estimates made in accordance with such policies are regularly discussed with the Audit Committee of the Company’s board of directors. We believe the following critical accounting policies involve the most significant judgments and estimates used in the preparation of the consolidated financial statements:
| ● | Research and development; | |
| ● | Stock-based compensation; and | |
| ● | Warrant liability. |
Quantitative and Qualitative Disclosure About Market Risk
Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Fixed rate securities may have their market value adversely affected due to a rise in interest rates. Accordingly, our future investment income may fluctuate as a result of changes in interest rates, or we may suffer losses in principal if we are forced to sell securities that decline in market value as a result of changes in interest rates.
Historically, we have raised capital through the issuance of equity securities. We had no long-term debt outstanding as of September 30, 2026 and December 31, 2025.
We do not believe that our cash and cash equivalents have significant risk of default or illiquidity. Our cash and cash equivalents consist primarily of cash, U.S. treasury bills and money market funds. Our exposure to market risk relating to cash and cash equivalents due to changes in interest rates is limited because our cash and cash equivalents have a short-term maturity and are used primarily for working capital purposes. While we believe our cash, cash equivalents and marketable securities do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions from time to time may be in excess of federally insured limits. Interest bearing and non-interest bearing accounts we hold at banking institutions are guaranteed by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. From time to time, some of our cash balances held at banking institutions may be in excess of FDIC coverage. We consider this to be a normal business risk.
We formed a wholly owned subsidiary, Lantern Pharma Australia Pty Ltd, in Australia in September 2021 and experienced foreign currency gains of approximately $87,000 and $138,000 for the nine months ended September 30, 2026 and 2025, respectively, in connection with this subsidiary. We will remain subject to the risk of foreign currency losses in future periods, although we do not expect the impact of any foreign currency losses to be material. We do not participate in any foreign currency hedging activities.
Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect on our results of operations during the periods presented. Inflation could have a greater impact on our future results of operations if it remains at current levels or increases.
| 30 |
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
As a Smaller Reporting Company we are exempt from the requirements of Item 3.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures.
Our management, with the participation of our Interim Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2026. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Based on such evaluation of our disclosure controls and procedures as of September 30, 2026, our Interim Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures, as defined above, are effective at the reasonable assurance level.
Changes in Internal Control Over Financial Reporting.
There were no changes in our internal control over financial reporting that occurred during the three months ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Inherent Limitations on Effectiveness of Controls.
Our management, including our principal executive officer and principal financial officer, do not expect that our disclosure controls or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
| 31 |
PART II – OTHER INFORMATION
Item 1A. Risk Factors.
We are not currently in compliance with the Nasdaq Capital Market’s minimum market value of listed securities (“MVLS”) requirement of $35 million and $1.00 minimum bid price requirement. If our common stock is delisted from the Nasdaq Capital Market, the market price and liquidity of our common stock and our ability to raise additional capital would be adversely impacted.
Our common stock is currently listed on the Nasdaq Capital Market. Continued listing of a security on the Nasdaq Capital Market is conditioned upon compliance with various continued listing standards. On September 25, 2026, we received a letter (the “Notice”) from the Nasdaq Stock Market (“Nasdaq”) notifying us that we did not met the $35 million minimum market value of listed securities required to maintain continued listing on the Nasdaq Capital Market as set forth in Nasdaq Marketplace Rule 5550(b)(2) (the “MVLS Requirement”).
As provided in the Nasdaq rules, we have 180 calendar days, or until March 24, 2027 (the “Compliance Date”), to regain compliance. To regain compliance, the market value of our listed securities must close at $35 million or more for a minimum of 10 consecutive business days at any time prior to March 24, 2027. In the event we do not regain compliance with the MVLS Requirement prior to the Compliance Date or we are not able to continue to meet other continued listing standards, including the minimum bid price of $1.00 as described below, Nasdaq will notify us that our securities are subject to delisting, at which point we may appeal the delisting determination to a Nasdaq hearings panel.
In addition, on November 13, 2026, we received a notice (“Minimum Bid Notice”), from Nasdaq, that we were not in compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2), or the Minimum Bid Price Requirement. The Minimum Bid Notice indicated that, consistent with Nasdaq Listing Rule 5810(c)(3)(A), we have 180 days, or until May 12, 2027, to regain compliance with the Minimum Bid Price Requirement by having the bid price of our common stock meet or exceed $1.00 per share for a minimum of ten consecutive business days. We may also be eligible for an additional compliance period of 180 calendar days if, on May 12, 2027, we meet the continued listing requirement for market value of publicly held shares and all other applicable standards for initial listing on the Nasdaq Capital Market (with the exception of the closing bid price requirement) based on our then most recent public filings and market information, and we provide written notice to Nasdaq of our intent to cure the deficiency during such additional compliance period, including, without limitation, by effecting a reverse stock split, if necessary.
The Notice and Minimum Bid Notice has no immediate effect on the listing of the Company’s securities on Nasdaq Capital Market. We intend to actively monitor our MVLS and Minimum Bid Price Requirement between now and the compliance dates, and may, if appropriate, evaluate available options including by effecting a reverse stock split to resolve the deficiencies and regain compliance with the requirements. While we are exercising diligent efforts to maintain the listing of our securities on the Nasdaq, there can be no assurance that we will be able to regain or maintain compliance with Nasdaq Capital Market listing standards.
If our common stock were delisted from the Nasdaq, trading of our common stock would most likely take place on an over-the-counter market established for unlisted securities, such as the OTCQB Venture Market operated by OTC Markets Group. An investor would likely find it less convenient to sell, or to obtain accurate quotations in seeking to buy, our common stock on an over-the-counter market, and many investors would likely not buy or sell our common stock due to difficulty in accessing over-the-counter markets, policies preventing them from trading in securities not listed on a national exchange or other reasons. In addition, as a delisted security, our common stock would be subject to SEC rules as a “penny stock,” which impose additional disclosure requirements on broker-dealers. The regulations relating to penny stocks, coupled with the typically higher cost per trade to the investor of penny stocks due to factors such as broker commissions generally representing a higher percentage of the price of a penny stock than of a higher-priced stock, would further limit the ability of investors to trade in our common stock.
| 32 |
Item 5. Other Information.
Proposed Settlement of Claim
In November 2026, the Company reached an agreement in principle regarding a settlement agreement with a former part-time consultant asserting claims of disability discrimination, sexual harassment and related claims. Under the terms of the proposed settlement (the “Proposed Settlement”), the Company would pay the claimant a total of $2,000,000, consisting of $1,000,000 within 30 days of the effective date of the settlement agreement and $1,000,000 upon the earlier of (i) the date on which the Company has raised, in the aggregate and whether in a single transaction or a series of transactions occurring after the effective date of the settlement agreement, at least $10,000,000 in gross cash proceeds through investment in the Company, the sale of the Company’s assets, or the out-licensing of the Company’s patents and (ii) the two year anniversary of the first payment.
Although the Proposed Settlement is not yet finalized and is not yet effective, the Company believes the terms of the Proposed Settlement are the best estimate of loss with respect to this matter, and the Company has accrued $2,000,000 in accounts payable and accrued expenses on its condensed consolidated balance sheet as of September 30, 2026 relating to this matter. The corresponding expense is included in general and administrative expenses in the Company’s condensed consolidated statements of operations for the three months and nine months ended September 30, 2026. It is possible this estimate could change in the near term, and the change may be material to the Company’s condensed consolidated financial statements.
Resignation of CEO; Appointment of Interim CEO
On November 15, 2026, Panna Sharma resigned as President and Chief Executive Officer of the Company, effective as of November 15, 2026. Mr. Sharma also resigned from the Company’s board of directors (“Board”) effective as of November 15, 2026.
Effective November 16, 2026, the Board has appointed David Margrave, current Chief Financial Officer of the Company, as Interim Chief Executive Officer until the Company appoints a permanent Chief Executive Officer. The Board intends to promptly commence a search for a successor.
Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard; Transfer of Listing
On November 13, 2026, the Company received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock (the “Common Stock”) had closed below the $1.00 per share minimum bid price requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).
The Notice has no immediate effect on the listing of the Common Stock, which continues to trade on The Nasdaq Capital Market under the symbol “LTRN.” In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has an initial compliance period of 180 calendar days, or until May 12, 2027, to regain compliance with the Minimum Bid Price Requirement.
To regain compliance, the closing bid price of the Company’s Common Stock must be at least $1.00 per share for a minimum of 10 consecutive business days during the 180-day compliance period ending May 12, 2027, as required under Nasdaq Listing Rule 5810(c)(3)(A), and the Company must otherwise satisfy The Nasdaq Capital Market’s requirements for listing.
If the Company does not regain compliance during the initial 180-day compliance period, the Company may be provided a second 180 calendar day period to regain compliance. To qualify, the Company must meet the continued listing requirement for market value of publicly-held shares and all other initial listing standards for the Nasdaq Capital Market (with the exception of the Minimum Bid Price Requirement), based on the Company’s most recent public filings and market information and notify Nasdaq of its intent to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If the Company does not regain compliance within the allotted compliance periods, including any extensions that may be granted by Nasdaq, the Company’s stock will be subject to delisting.
The Company is actively monitoring the closing bid price of its Common Stock and will consider all available options to regain compliance with the Minimum Bid Price Requirement. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement during the 180-day compliance period, secure a second 180-day period to regain compliance, maintain compliance with the other Nasdaq listing requirements or be successful in appealing any delisting determination.
As previously disclosed in the Company’s Current Report on Form 8-K filed with the SEC on October 1, 2026, the Company received a separate notice from Nasdaq indicating that the Company did not comply with the minimum market value of listed securities (“MVLS”) requirement set forth in Nasdaq Listing Rule 5550(b)(2). The Company was given until March 24, 2027 to regain compliance with the MVLS requirement. The notice concerning the Minimum Bid Price Requirement above does not affect the compliance period to regain compliance with the MVLS requirement. The Company’s ability to obtain an additional compliance period for the Minimum Bid Price Requirement may depend on, among other things, its satisfaction of the applicable continued and initial listing requirements of The Nasdaq Capital Market.
| 33 |
Item 6. Exhibits.
| Exhibit No. | Exhibit Description | Method of Filing | ||
| 3.1 | Amended and Restated Certificate of Incorporation | Incorporated by reference from the Registrant’s Current Report on Form 8-K filed June 17, 2020 | ||
| 3.2 | By-Laws | Incorporated by reference from the Registrant’s Registration Statement on Form S-1 filed April 16, 2020 | ||
| 3.3 | Amendment No. 1 to By-Laws | Incorporated by reference from the Registrant’s Current Report on Form 8-K filed May 24, 2024 | ||
| 3.4 | Amendment No. 2 to By-Laws | Incorporated by reference from Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed July 29, 2025 | ||
| 4.1 | Form of Pre-Funded Common Stock Purchase Warrant from September 2026 Offering | Incorporated by reference from the Registrant’s Current Report on Form 8-K filed September 30, 2026 | ||
| 4.2 | Form of Purchase Warrant from September 2026 Offering | Incorporated by reference from the Registrant’s Current Report on Form 8-K filed September 30, 2026 | ||
| 4.3 | Form of Placement Agent Warrant from September 2026 Offering | Incorporated by reference from the Registrant’s Current Report on Form 8-K filed September 30, 2026 | ||
| 10.1 | Securities Purchase Agreement from September 2026 Offering | Incorporated by reference from the Registrant’s Current Report on Form 8-K filed September 30, 2026 | ||
| 31.1 | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | Filed electronically herewith | ||
| 31.2 | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | Filed electronically herewith | ||
| 32.1 | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | Furnished electronically herewith | ||
| 32.2 | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | Furnished electronically herewith | ||
| 101.INS | Inline XBRL Instance Document. | Filed electronically herewith | ||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. | Filed electronically herewith | ||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | Filed electronically herewith | ||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. | Filed electronically herewith | ||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. | Filed electronically herewith | ||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | Filed electronically herewith | ||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). | Filed electronically herewith |
| 34 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Lantern Pharma Inc., | ||
| A Delaware Corporation | ||
| Dated: November 17, 2026 | By: | /s/ David R. Margrave |
| David R. Margrave, Chief Executive Officer | ||
| Dated: November 17, 2026 | By: | /s/ David R. Margrave |
| David R. Margrave, Chief Financial Officer | ||
| 35 |